Research Reports

Summary

Apyx Medical Corporation announced publication of a retrospective clinical study showing statistically significant improvements in patient-reported satisfaction and reduced abdominoplasty and revision rates when Renuvion® was used with liposuction, reinforcing clinical value for its AYON Body Contouring System™.

Key takeaways

Renuvion + liposuction group showed higher patient satisfaction with abdominal appearance (68.8 vs. 45.0; p=0.039) versus power-assisted liposuction alone.

Abdominoplasty rate was more than 50% lower in the Renuvion group (30.0% vs. 67.1%), indicating potential reduction in downstream surgical procedures.

Revision rates were significantly lower with Renuvion (12.0% vs. 37.5%; p=0.038), suggesting improved primary procedure efficacy and reduced rework.

Complication rates remained comparable between groups (2.5% vs. 2.7%), supporting safety profile consistency for Renuvion integration.

The 113-patient study was investigator-initiated, retrospective, and led by Dr. Pablo D. Huber, evaluating long-term (>12 month) Body-Q® outcomes.

Full analysis

This clinical publication provides peer-reviewed, real-world evidence supporting the differentiated clinical benefits of Apyx’s Renuvion technology when combined with liposuction — specifically higher patient satisfaction, lower rates of secondary procedures (abdominoplasty and revisions), and maintained safety. While not an earnings or regulatory event, it strengthens the clinical narrative underpinning AYON’s commercial positioning, especially following the October 2025 510(k) filing for AYON label expansion to include power liposuction. The study’s single-surgeon, retrospective design limits generalizability, but its focus on validated, patient-reported outcomes (Body-Q®) and statistically significant endpoints adds credibility to claims about aesthetic improvement and procedural efficiency. For investors, this reinforces the evidence-based foundation for Apyx’s commercial messaging and may support adoption momentum for AYON, though no revenue impact, guidance, or financial metrics are disclosed.